New cancer drug begins first human testing
NCT ID NCT04617314
Summary
This early-stage study tested a new cancer drug called RC108-ADC in 67 patients with advanced solid tumors that had a specific marker (c-Met positive). The main goals were to find the highest safe dose and check for side effects. Researchers also measured how the drug moved through the body and whether tumors shrank in response to treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
-
The First Hospital of Jilin University
Changchun, Jilin, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.